ArticleClinical kidney journal2022

Evaluating the impact of a Risk Evaluation and Mitigation Strategy with tolvaptan to monitor liver safety in patients with autosomal dominant polycystic kidney disease.

Alvin Estilo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.